Clinical trials update AHA congress 2010

Cardiovascular Drugs and Therapy

Volumn 25, Issue 1, 2011, Pages 69-76

  Horowitz, John D ^a   Rosenson, Robert S ^b   McMurray, John J V ^c   Marx, Nikolaus ^d   Remme, Willem J ^e  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

AHA congress; ASCEND; ASSERT; CTTC; CUPID; DEFINE; EMPHASIS HF; GRAVITAS; Late breaking trials; PROTECT; Randomized controlled trials; REVEAL

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANACETRAPIB; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALCETRAPIB; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ERYTHROPOIETIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYDICAR; NESIRITIDE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; RVX 208; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SPIRONOLACTONE; TORCETRAPIB; UNCLASSIFIED DRUG; VIRUS VECTOR;

ACUTE HEART FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; UNITED STATES;

EID: 79960003546     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6285-9     Document Type: Conference Paper

References (23)

1. Zannad F, McMurray JJ, Krum H, et al. Epleronone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
2. Melloni C, Rao SV, Povsic TJ, et al. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodelling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010;160:795-803.
3. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009;157:818-24.
4. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndrome. N Engl J Med. 2010;363:930-42.
5. Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006;151:556-63. (Pubitemid 43290244)
6. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333-9.
7. Keech AC, Rosenson R, Barnes E, et al. Low HDL-C carries residual risk even at target LDL-C among patients in the Cholesterol Treatment Trialists' Collaboration Studies. Circulation. 2010;122: A19010.
8. Krishna R,AndersonMS, BergmanAJ, et al. Effect of the cholesterol ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907-14. (Pubitemid 350192656)
9. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-60.
10. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patient with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-15.
11. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443-54.
12. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux in HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132-8. (Pubitemid 46641969)
13. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler-ThrombVasc Biol. 2010;30:1430-8.
14. Vucic E, Rosenson RS. Recombinant HDL formulations. Curr Athero Rep. 2011;13:81-7.
15. Nissen S, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled clinical trial. JAMA. 2003;290:2292-300. (Pubitemid 37430562)
16. Nichols SJ, Ballantyne CM, Kastelein JJ, et al. Results of the first major clinical trial of an oral agent inducing Apo A1 synthesis: A new approach to HDL raising and CV risk modification. Circulation. 2010;122:2220.
17. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler ThrombVasc Biol. 2003;23:847-52. (Pubitemid 36566176)
18. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185-91. (Pubitemid 41416319)
19. Pitt B, Remme WJ, Zannad F, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. (Pubitemid 36384098)
20. Pitt B, Zannad F, Remme WJ, for the Randomized ALdactone Evaluation Study (RALES) Investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
21. Kawakase Y, Ly H, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:554-65.
22. Cohn J. Unconventional end points in cardiovascular trials: should we be moving away from morbidity and mortality? J Card Fail. 2009;15:199-205.
23. Jaski B, Jessup M, Mancini D, et al. for the CUPID Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15:171-81.